BR112023023951A2 - Compostos espiroindolinona como bloqueadores de canais shaker kv1.3 de potássio - Google Patents
Compostos espiroindolinona como bloqueadores de canais shaker kv1.3 de potássioInfo
- Publication number
- BR112023023951A2 BR112023023951A2 BR112023023951A BR112023023951A BR112023023951A2 BR 112023023951 A2 BR112023023951 A2 BR 112023023951A2 BR 112023023951 A BR112023023951 A BR 112023023951A BR 112023023951 A BR112023023951 A BR 112023023951A BR 112023023951 A2 BR112023023951 A2 BR 112023023951A2
- Authority
- BR
- Brazil
- Prior art keywords
- shaker
- channel blockers
- potassium
- spiroindolinone
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 title 1
- 229910052700 potassium Inorganic materials 0.000 title 1
- 239000011591 potassium Substances 0.000 title 1
- 102000018706 Kv1.3 Potassium Channel Human genes 0.000 abstract 1
- 108010027296 Kv1.3 Potassium Channel Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003450 potassium channel blocker Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
compostos espiroindolinona como bloqueadores de canais shaker kv1.3 de potássio. a presente invenção refere-se a um composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, é descrito, em que os substituintes são como definidos aqui. composições farmacêuticas que compreendem as mesmas e método de uso das mesmas são também descritos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163194599P | 2021-05-28 | 2021-05-28 | |
| PCT/US2022/031229 WO2022251561A2 (en) | 2021-05-28 | 2022-05-27 | Spiroindolinone compounds as kv1.3 potassium shaker channel blockers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023023951A2 true BR112023023951A2 (pt) | 2024-01-30 |
Family
ID=84230386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023023951A BR112023023951A2 (pt) | 2021-05-28 | 2022-05-27 | Compostos espiroindolinona como bloqueadores de canais shaker kv1.3 de potássio |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP4351569A2 (pt) |
| JP (1) | JP2024522280A (pt) |
| KR (1) | KR20240001192A (pt) |
| CN (1) | CN117597120A (pt) |
| AR (1) | AR125994A1 (pt) |
| AU (1) | AU2022281402A1 (pt) |
| BR (1) | BR112023023951A2 (pt) |
| CA (1) | CA3219345A1 (pt) |
| CO (1) | CO2023016088A2 (pt) |
| CR (1) | CR20230555A (pt) |
| DO (1) | DOP2023000257A (pt) |
| EC (1) | ECSP23089582A (pt) |
| IL (1) | IL308277A (pt) |
| TW (1) | TW202310831A (pt) |
| WO (1) | WO2022251561A2 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023141432A2 (en) | 2022-01-18 | 2023-07-27 | Maze Therapeutics, Inc. | Apol1 inhibitors and methods of use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4345081A (en) * | 1980-02-15 | 1982-08-17 | American Hoechst Corporation | Spiro[indoline-3,4'-piperidine]s |
| EP2108641A1 (en) * | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
-
2022
- 2022-05-27 EP EP22812208.1A patent/EP4351569A2/en active Pending
- 2022-05-27 KR KR1020237040381A patent/KR20240001192A/ko active Search and Examination
- 2022-05-27 BR BR112023023951A patent/BR112023023951A2/pt unknown
- 2022-05-27 TW TW111119802A patent/TW202310831A/zh unknown
- 2022-05-27 AU AU2022281402A patent/AU2022281402A1/en active Pending
- 2022-05-27 CN CN202280038587.8A patent/CN117597120A/zh active Pending
- 2022-05-27 AR ARP220101414A patent/AR125994A1/es unknown
- 2022-05-27 CR CR20230555A patent/CR20230555A/es unknown
- 2022-05-27 CA CA3219345A patent/CA3219345A1/en active Pending
- 2022-05-27 WO PCT/US2022/031229 patent/WO2022251561A2/en active Application Filing
- 2022-05-27 IL IL308277A patent/IL308277A/en unknown
- 2022-05-27 JP JP2023573161A patent/JP2024522280A/ja active Pending
-
2023
- 2023-11-23 CO CONC2023/0016088A patent/CO2023016088A2/es unknown
- 2023-11-24 DO DO2023000257A patent/DOP2023000257A/es unknown
- 2023-11-27 EC ECSENADI202389582A patent/ECSP23089582A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20230555A (es) | 2024-02-19 |
| AR125994A1 (es) | 2023-08-30 |
| CN117597120A (zh) | 2024-02-23 |
| KR20240001192A (ko) | 2024-01-03 |
| EP4351569A2 (en) | 2024-04-17 |
| WO2022251561A2 (en) | 2022-12-01 |
| WO2022251561A3 (en) | 2023-01-05 |
| TW202310831A (zh) | 2023-03-16 |
| IL308277A (en) | 2024-01-01 |
| ECSP23089582A (es) | 2023-12-29 |
| CO2023016088A2 (es) | 2024-02-26 |
| JP2024522280A (ja) | 2024-06-13 |
| CA3219345A1 (en) | 2022-12-01 |
| AU2022281402A1 (en) | 2023-11-02 |
| DOP2023000257A (es) | 2023-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021021718A2 (pt) | Moduladores de thr-ss e métodos de uso dos mesmos | |
| BR112022018140A2 (pt) | Compostos pirimidoheterocíclicos e aplicação dos mesmos | |
| BR112022006202A2 (pt) | Compostos heterocíclicos de arila como bloqueadores de canal do agitador de potássio kv1,3 | |
| EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
| BR112022006242A2 (pt) | Compostos aromáticos de arilmetileno como bloqueadores de canal do agitador de potássio kv1,3 | |
| BR112021007788A8 (pt) | Composto inibidor de jak 2-azabiciclo hexano | |
| BR112022003982A2 (pt) | Compostos heterocíclicos | |
| BR112023023951A2 (pt) | Compostos espiroindolinona como bloqueadores de canais shaker kv1.3 de potássio | |
| BR112021020297A2 (pt) | Compostos de hexa-hidro-1h-pirazino[1,2-a]pirazina para o tratamento de doença autoimune | |
| AR116713A1 (es) | COMPUESTOS DE IMIDAZOLINDIONA COMO REGULADORES DE CANALES Kv3 | |
| PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
| BR112022010441A2 (pt) | Análogos de equinocandina e método de preparação para os mesmos | |
| BR112023006312A2 (pt) | Composto, métodos para preparar o composto, composição farmacêutica e uso do composto | |
| CU20230009A7 (es) | Composiciones farmacéuticas que comprenden compuestos derivados de (r)-n-(5-(3-hidroxipirrolidin-1-il)-2-morfolinooxazolo[4,5-b]piridin-6- il)-2-(2-metilpiridin-4-il) oxazol-4 -carboxamida, útiles como inhibidores de irak | |
| PH12020551342A1 (en) | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | |
| ECSP22027784A (es) | Derivados de 2azaespiro[3.4]octano como agonistas de m4 | |
| BR112022006507A2 (pt) | Compostos heterocíclicos de arilmetileno como bloqueadores de canais de agitador de potássio kv1.3 | |
| CL2022000893A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| BR112022006250A2 (pt) | Compostos heterobicíclicos de arila como bloqueadores de canal de agitador de potássio kv1.3 | |
| BR112023001962A2 (pt) | Forma sólida de composto | |
| BR112022006292A2 (pt) | Compostos heterobicílicos de arila como bloqueadores de canais de agitador de potássio kv1.3 | |
| BR112023005387A2 (pt) | Compostos lactam como bloqueadores de canais agitadores de potássio kv1.3 | |
| BR112023015721A2 (pt) | Derivados tricíclicos úteis como inibidores de parp7 | |
| BR112023018505A2 (pt) | Compostos heterocíclicos de arila como bloqueadores de canais shaker kv1.3 de potássio | |
| MX2023002068A (es) | Nuevos compuestos que tienen actividad inhibidora sobre el receptor de prostaglandina e2 y usos de los mismos. |